Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
87 participants
OBSERVATIONAL
2023-07-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Regardless of the type of CA, TTR or AL, early diagnosis significantly improves prognosis.
In this study, the investigators aimed to determine the prevalence of CA in Tunisian HFpEF patients and to identify clinical and ultrasound criteria predictive of CA.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Amyloidosis in Heart Failure (PREVAMIC)
NCT04066452
Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
NCT04915235
Identification of Prognostic Parameters in Patients With " Senile " Amyloid Cardiomyopathy
NCT04225754
Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)
NCT05064839
Cardiac Amyloidosis in HFpEF
NCT04587648
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* IVS thickness of 12mm or greater
Exclusion Criteria
* Acute coronary syndrome complicated by HFpEF
* Congenital heart disease
60 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Tunis El Manar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lilia Zakhama
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lilia Zakhama, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Security Hospital Forces
La Marsa, Tunis Governorate, Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.